跳至主要内容
临床试验/NCT06708000
NCT06708000Enrolling By Invitation3 期

Personalized Evaluation of Suspected Myocardial Ischemia

Gødstrup Hospital2 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2024年11月20日最近更新:
适应症

试验速览

阶段
3 期
状态
Enrolling By Invitation
发起方
入组人数
2,000
试验地点
2
主要终点
Proportion of Asymptomatic Patients 6 Months After Inclusion

研究概览

简要总结

This study aims to assess whether the use of clinical risk models, known as Clinical Likelihood (CL) models, can reduce the need for diagnostic examinations without negatively impacting quality of life or prognosis after 12 months in patients with stable new onset chest pain. Additionally, the project will evaluate a newly developed method called Laser Speckle Contrast Imaging for measuring function and oxygen content in the smallest blood vessels (microvasculature) of the hand, which may also reflect blood flow and oxygen content in the microvasculature of the heart.

详细描述

Ischemic heart disease poses a significant burden on society and affects many Danes annually. With more than 300,000 citizens in Denmark living with cardiovascular disease, and more than 17,500 cardiovascular deaths annually, the need for effective diagnosis and treatment is crucial. Cardiac Computed Tomography Angiography (CCTA) has become an important tool in diagnosing arteriosclerotic obstructive coronary artery disease (CAD) in patients with typical or atypical chest pain, but the increasing use of this method requires a more efficient selection of patients before initial testing. Early and accurate risk stratification could improve patient management, reduce morbidity, and improve patient outcomes, highlighting the importance of optimizing diagnostic pathways.

At Gødstrup Hospital, novel clinical likelihood (CL) models have been developed to assess the pre-test probability of obstructive CAD. Based on sex, age, and symptom characteristics, and including traditional cardiovascular risk factors, the risk factor-weighted clinical likelihood (RF-CL) model improves discrimination of obstructive CAD and prognosis compared to traditional models. Additionally, the utilization of a coronary artery calcium score (CACS) in conjunction with the RF-CL model, i.e., the CACS-weighted clinical likelihood (CACS-CL) model, further enhances patient management in external validation cohorts. Recently, both CL models have been implemented in the European guidelines on CAD management. However, the CL models have only been applied in observational studies, and no randomized trials substantiate their use in clinical practice.

It is hypothesized that a diagnostic strategy based on an assessment including the CL models is non-inferior to the current standard strategy, as measured by the number of asymptomatic patients during follow-up. Secondly, it is assumed that the CL-based strategy reduces unnecessary diagnostic tests and improve resource utilization without compromising patient safety.

Emerging alongside these developments is Laser Speckle Contrast Imaging (LSCI), a promising non-invasive technique for assessing microvascular function. Several studies have suggested a link between reduced microcirculation in the skin and heart among patients with angina and non-significant calcification, compared to healthy controls. LSCI measures red blood cell movement to quantify blood flow, making it an effective, fast, and cost-efficient tool already in use in other medical fields. If a correlation between peripheral and cardiac microcirculation is established, LSCI could address a diagnostic gap in detecting microvascular dysfunction, particularly for angina patients without significant coronary calcification. Integrating LSCI into the diagnostic process offers potential to further refine patient selection for testing and provide more targeted diagnostic pathways.

This study will increase the evidence for utilizing the RF-CL and CACS-CL models in clinical practice. Currently, the use of pre-test likelihood models is only recommended with a IB recommendation and deferral of diagnostic testing in individuals with CL>=5% with IIa B recommendation due to a lack of randomized studies. The study will focus on symptomatic endpoints and investigate quality of life measurements in patients deferred for testing based on the CL estimation. Secondary endpoints include both effectiveness and safety metrics.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Single (Investigator)

盲法说明

The randomization will be conducted in a 1:1 ratio using an internet-based randomization solution.

Then, patients will be randomly assigned to either the control group or the intervention group, and regardless of study allocation and initial RF-CL assessement, all patients will then receive an initially blinded CCTA. The cardiologist conducting the CCTA is unaware of the patient's randomization status.

Patients in the intervention group with a clinical likelihood of obstructive CAD (RF-CL) ≤5% will receive a blinded CCTA.

Patients in the intervention group with RF-CL >5% will undergo a CACS assessment to estimate a CACS-CL.

Patients in the control group, and patients in the intervention group with a CL >5%, will receive their test results, including unblinding of the results from the CCTA.

Patients in the intervention group with CL≤5% will also receive their test results, except for the CCTA results which remain blinded.

The interviewer at follow-up is unaware of the CCTA result.

入排标准

年龄范围
30 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with de novo chest pain referred on suspicion of stable ischemic CAD
  • Patients capable of providing written informed consent

排除标准

  • Age <30 years or >75 years
  • Known ischemic heart disease, including previous PCI (with or without stent) and bypass surgery
  • Unstable angina pectoris at initial consultation
  • Severe COPD or asthma
  • Severe valvular disease
  • Absolute or relative contraindications for Cardiac CT:
  • allergy to iomeron
  • pregnant women, including women who are potentially pregnant or lactating
  • reduced kidney function with an estimated glomerular filtration rate <40 ml/min
  • LVEF <45%

结局指标

主要结局

Proportion of Asymptomatic Patients 6 Months After Inclusion

时间窗: From enrollment to 6 months after patient inclusion

Resolution 6 months after inclusion, as assessed by SAQ Angina Frequency score of 100%, indicating the absence of angina-related symptoms. This measure will assess the effectiveness of a diagnostic strategy based on Clinical Likelihood (CL) models compared to the standard approach for evaluating patients suspected of stable ischemic heart disease (IHD).

次要结局

  • Sensitivity and Specificity for Detecting Obstructive Coronary Artery Disease (CAD)(From enrollment to 12 months after patient inclusion.)
  • Proportion of Patients Undergoing Cardiac CT Imaging(From enrollment to 12 months after patient inclusion)
  • Seattle Angina Questionnaire (SAQ) Scores for Quality of Life(3, 6, and 12 months after enrollment)
  • Dyspnea Assessment: Rose Dyspnea Score for Symptom Evaluation(3, 6 and 12 months after enrollment)
  • Correlation Between Peripheral and Cardiac Microvascular Function via LSCI(At baseline and 6 months after enrollement)
  • Long-term prognosis(10 years)

研究者

发起方
Gødstrup Hospital
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验